Project Grant R61CA291202
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$217K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Chestnut Hill, Newton, MA, USA
Similar Awards
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $775,000 in funding to Trustees of Boston College (Boston College) over a 5-year period from Sep 2024 to Aug 2029. The award will support research focused on expanding the chemical and functional space of boron-nitrogen heterocycles, with the goal of enabling new reactivity, selectivity, and mechanistic principles in...
This federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) provides $635,248 to Trustees of Boston University to develop a modified self-amplifying ribonucleic acid (SARNA) technology encoding for a bispecific T cell engaging (BiTE) antibody to treat lung cancer. The key product is the 5-methylcytidine (5MC) modified SARNA construct encoding the BiTE antibody, which aims to enhance protein expression, reduce innate immune...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Dana-Farber Cancer Institute, Inc. (DFCI) in the amount of $942,442. The grant, awarded on September 1, 2024, will support research to identify the mechanisms driving rapid evolution of cancer genomes, with a focus on understanding catastrophic mutational processes like chromothripsis and chromoplexy. The research, conducted at DFCI's facilities in Boston, MA,...
This $407,113 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will fund research by Trustees of Boston University to develop a new bio-orthogonal mid-infrared photothermal (MIP) imaging technology to study cancer metabolism. The key products and services to be delivered include: Building a library of nitrile-based probes to sense important molecular events and nutrient metabolism in cancer cells using the MIP imaging approach. Developing a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $380,337 to the University of Washington to develop improved mRNA therapy design algorithms. The key objectives are to: Develop massively parallel reporter assays (MPRAs) to measure mRNA sequence effects on stability and translation across cell types. Leverage machine learning to build predictive models integrating MPRA data and enable generation of synthetic mRNA sequences with...
This $215,564 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports the development of novel "AEGIS-based" reagents that can selectively bind to and cleave cancer-relevant proteins like PD-L1. The awarded organization, Foundation For Applied Molecular Evolution, Inc., will apply its proprietary "AEGIS-LIVE" platform to create specialized "AEGISBODIES" and "AEGISCLEAVERS" that can quantitatively...
This $750,000 Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences (CFDA 47.049) program supports the development of a novel platform to enable rapid and robust identification of functional RNA molecules directly within mammalian cellular environments. The research aims to solve the challenge of RNA structure sensitivity to local environments that has hindered progress in the field of functional RNA discovery. The project will deliver a customized...
This $427,095 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of a novel microfluidic droplet-based platform (MDP) technology at Northeastern University. The objective is to generate and analyze a 3D biomimetic multicellular immunogenic tumor model that can establish multiple levels of hypoxia, investigate spatiotemporal interactions between the tumor microenvironment and...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to The Broad Institute, Inc. (doing business as Broad Institute of MIT and Harvard) for a 3-year project from August 1, 2024 to July 31, 2027. The grant will fund the development of a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis". The project aims to extend the institute's "Slide-Tags"...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at understanding and engineering durable chimeric antigen receptor (CAR) T-cell therapies for solid tumor cancers. The key focus is on deconvolving the heterogeneity of CAR T-cell populations to identify strategies for programming optimal effector and memory T-cell responses. The research will utilize...